Search

Tetsuya Taura

from Palo Alto, CA
Age ~60
Get Report
Also known as:
Tetsuya Akamatsu, Tesuya Akamatsu, Tesuya E
Phone and address:
514 Driscoll Pl, Palo Alto, CA 94306
Related to:
Yoshiko Akamatsu, 58Ray T Akamatsu
Connected to:
Elizabeth D Tauranac, 79Arvydas P Tauras, 85Norman Taurean, 43Justin R Taurence, 37Connie M Tauriac, 65Margery A Tauriainen, 58Ryan G Tauriainen, 39David M Taurino, 61Massimo Taurisano, 56Chastian Taurman, 46

Tetsuya Taura Phones & Addresses

  • 514 Driscoll Pl, Palo Alto, CA 94306
  • Fremont, CA
  • Boston, MA

Work

Company: Arana therapeutics, inc. Position: Senior scientist

Education

School / High School: Kyoto University 1988 to 1993

Skills

Japanese • San

Languages

Japanese

Industries

Biotechnology

Resumes

Resumes

Tetsuya Taura Photo 1

Senior Scientist

View page
Location:
Palo Alto, CA
Industry:
Biotechnology
Work:
Arana Therapeutics, Inc.
Senior Scientist
Education:
Kyoto University 1988 - 1993
Skills:
Japanese
San
Languages:
Japanese

Publications

Us Patents

Modified Antibody With Improved Half-Life

View page
US Patent:
20130281677, Oct 24, 2013
Filed:
Dec 22, 2011
Appl. No.:
13/996733
Inventors:
David Wilson - Fremont CA, US
Tetsuya Taura - Palo Alto CA, US
Assignee:
Cephalon Australia Pty, Ltd. - Macquarie Park, NSW
International Classification:
C07K 16/00
US Classification:
5303891
Abstract:
The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.

Anti-Pamp Therapeutic Antibodies

View page
US Patent:
20110301332, Dec 8, 2011
Filed:
Jul 1, 2009
Appl. No.:
13/001744
Inventors:
David Wilson - Fremont CA, US
Tetsuya Taura - Palo Alto CA, US
Assignee:
Cephalon Australia (VIC) Pty Ltd. - Parkville, Victoria
International Classification:
C07K 16/18
C12N 5/18
US Classification:
5303873, 5303879, 435331
Abstract:
The invention relates to antibodies and antigen-binding fragments thereof which bind to proadrenomedullin N-terminal peptide (“PAMP”). Furthermore, the invention comprises monoclonal antibody EGX-P-E9 as well as engineered variants thereof, including chimeric, humanized or de-immunized versions thereof. The antibodies of the invention are useful for inhibiting the physiological activities of PAMP as well as in diagnosis of PAMP-responsive conditions.

Anti-Cd47 Combination Therapy

View page
US Patent:
20220259311, Aug 18, 2022
Filed:
Apr 29, 2022
Appl. No.:
17/733378
Inventors:
- New South Wales, AU
Tetsuya Taura - Redwood City CA, US
International Classification:
C07K 16/28
A61P 35/00
A61K 38/21
Abstract:
The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRPα receptor.

Anti-Cd47 Combination Therapy

View page
US Patent:
20200010544, Jan 9, 2020
Filed:
Jul 19, 2017
Appl. No.:
16/317077
Inventors:
- New South Wales, AU
Tetsuya TAURA - Redwood City CA, US
Assignee:
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD - New South Wales
International Classification:
C07K 16/28
A61K 38/21
A61P 35/00
Abstract:
The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type 1 interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRPα receptor.

Anti-Cd38 Antibodies And Fusions To Attenuated Interferon Alpha-2B

View page
US Patent:
20180305460, Oct 25, 2018
Filed:
Apr 19, 2018
Appl. No.:
15/957341
Inventors:
- Macquarie Park, AU
Matthew Pollard - Macquarie Park, AU
Anthony Gerard Doyle - Macquarie Park, AU
Collette Behrens - Macquarie Park, AU
Tetsuo Yamagishi - Macquarie Park, AU
Sarah L. Pogue - Fremont CA, US
Tetsuya Taura - Palo Alto CA, US
International Classification:
C07K 16/28
A61K 38/21
A61K 39/395
C07K 14/56
A61K 38/00
A61K 39/00
Abstract:
Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

Fusions Of Antibodies To Cd38 And Attenuated Interferon Alpha

View page
US Patent:
20170233449, Aug 17, 2017
Filed:
Mar 2, 2017
Appl. No.:
15/447912
Inventors:
- Macquarie Park, AU
Sarah L. Pogue - Freemont CA, US
Glen E. Mikesell - Pacifica CA, US
Tetsuya Taura - Palo Alto CA, US
Wouter Korver - Mountain View CA, US
Anthony G. Doyle - Drummoyne, AU
Adam Clarke - Five Dock, AU
Matthew Pollard - Dural, AU
Stephen Tran - Strathfield South, AU
Jack Tzu Chiao Lin - Redwood City CA, US
International Classification:
C07K 14/56
Abstract:
The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

Polypeptide Constructs And Uses Thereof

View page
US Patent:
20160367695, Dec 22, 2016
Filed:
Jun 28, 2016
Appl. No.:
15/194926
Inventors:
- Macquarie Park, AU
Sarah L. Pogue - Freemont CA, US
Glen E. Mikesell - Pacifica CA, US
Tetsuya Taura - Palo Alto CA, US
Wouter Korver - Mountain View CA, US
Anthony G. Doyle - Drummoyne, AU
Adam Clarke - Five Dock, AU
Matthew Pollard - Dural, AU
Stephen Tran - Strathfield South, AU
Jack Tzu Chiao Lin - Redwood City CA, US
International Classification:
A61K 47/48
C07K 16/28
Abstract:
The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

Anti-Cd38 Antibodies And Fusions To Attenuated Interferon Alpha-2B

View page
US Patent:
20160068612, Mar 10, 2016
Filed:
Oct 26, 2015
Appl. No.:
14/922282
Inventors:
- Macquarie Park, AU
Matthew Pollard - Macquarie Park, AU
Anthony Gerard Doyle - Macquarie Park, AU
Collette Behrens - Macquarie Park, AU
Tetsuo Yamagishi - Macquarie Park, AU
Sarah L. Pogue - Fremont CA, US
Tetsuya Taura - Palo Alto CA, US
International Classification:
C07K 16/40
C07K 16/28
C07K 14/56
Abstract:
Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
Control profile
Tetsuya Taura from Palo Alto, CA, age ~60 Get Report